INTRODUCTION

Antigen-specific antiviral B cell responses are a key component in the resolution of viral infections and maintenance of immune memory following pathogen clearance or immunisation. These responses are dependent on three principal factors: (a) the generation of antibodies to clear infection; (b) the diversification and evolution of antigen-specific responses; and (c) the persistence of long-lived immune memory. Effective and durable humoral responses are generated in germinal center (GC) reactions, whereby B cells undergo iterative rounds of clonal expansion and somatic hypermutation to generate a diverse pool of memory B cells and plasma cells. This process is critically dependent on specialized T follicular helper cells (T

Abstract

Humoral immunity is a critical component of the coordinated response required to resolve viral infections and mediate protection following pathogen clearance or vaccination. A better understanding of factors shaping the memory B cell response will allow tailored development of efficient preventative vaccines against emerging acute viral infections, therapeutic vaccines, and immunotherapies for chronic viral infections. Here, we use recent data obtained by profiling antigen-specific B cell responses in hepatitis B as a framework to explore lessons that can be learnt from different viral infections about the diverse influences on humoral immunity. Hepatitis B provides a paradigm where successful B cell responses in resolved or vaccinated individuals can be contrasted to the failed response in chronic infection, while also exemplifying the degree to which B cell responses within infected individuals can differ to two antigens from the same virus. Drawing on studies in other human and murine infections, including emerging data from COVID-19, we consider the influence of antigen quantity and structure on the quality of the B cell response, the role of differential CD4 help, the importance of germinal center vs extrafollicular responses and the emerging concept that responses residing in non-lymphoid organs can participate in B cell memory.

KEYWORDS

B cells, humoral immunity, memory B cell differentiation, viral infection
Although the roles of B cells in viral infections are diverse and wide-ranging, including immunoregulatory cytokine production and antigen presentation, this review will concentrate on findings from new studies in hepatitis B, SARS-CoV-2 infection and other human and murine infections to consider emerging concepts regarding the factors that govern memory B cell differentiation and their impact on humoral immunity.

2 | USING HBV AS A MODEL

From an immunological standpoint, Hepatitis B virus (HBV) infection provides a valuable setting to study differential B cell responses in humans, both between individuals (by comparing individuals with protective immunity to those without), and within individuals (by comparing B cell responses to different viral antigens). HBV is a DNA virus comprised of a partially double-stranded genome packaged within a nucleocapsid of HBV core antigen (HBcAg) and enveloped by an outer shell of HBV surface antigen (HBsAg). These surface antigens are responsible for facilitating viral binding and entrance into hepatocytes and thus constitute the major antigenic epitopes of the virus and target of prophylactic vaccination. Natural HBV infection results in divergent clinical outcomes, dependent largely on the age and immune competence of the individual at the time of infection. The majority of individuals will naturally resolve infection, establishing long-lasting immunity to the virus in the form of strong HBV-specific T cell responses and antibodies targeting both HBcAg and HBsAg (resulting in loss of serum HBsAg, although HBV DNA typically persists as cccDNA and integrated forms in hepatocytes). However, a portion of individuals infected, particularly those infected perinatally, develop a persistent infection, where the immune response fails to control the virus and can instead trigger tissue damage leading to life-threatening complications. While these patients do not display global defects in antibody production and maintain robust responses to HBcAg, chronic HBV infection (CHB) is characterized by an absence of detectable anti-HBs—indeed, the di-

ance and long-term suppression in HBV seroconverters and thus represents a key consideration in the use of Rituximab in the management of lymphoma) significantly increases the risk of HBV-reactivation in HBV-resolved patients and of viremic flares in chronically infected patients with low viral loads (HBsAg + inactive carriers). Long-lived plasma cells lack expression of CD20 and so should be preserved following Rituximab treatment; as a key cell population responsible for providing long-term antibody production, these cells might be expected to maintain serum antibody responses in the absence of memory B cells. The observation that Rituximab can lead to loss of humoral immunity in these settings therefore suggests that long-lived plasma cells may not be reliably formed following HBV infection, instead pointing to an ongoing role for CD20-expressing memory B cells or plasmablasts in mediating viral control. The manifestation of disease flares in chronic carriers without detectable anti-HBs upon Rituximab may also allude to roles for B cells beyond antibodies in this setting and/or a potential contribution of antibodies not detected by standard clinical assays (eg, sequestered in immune complexes). Recent studies have identified a dominance of broadly neutralizing antibodies (bnAbs) targeting HBsAg within the HBsAg-specific memory B cell responses in both HBV-vaccinated and naturally resolved individuals that demonstrate protective, neutralizing potential in vitro and in vivo models. These bnAbs appear to play a key role in viral clearance and long-term suppression in HBV seroconverters and thus represent a promising immunotherapeutic tool toward achieving HBV functional cure in patients with CHB.

3 | ANTIGEN-DRIVEN DETERMINATION OF MEMORY B CELL PROGRAMS

What can be learned from the dichotomous response to the surface and core antigens in hepatitis B about the role of antigen load
or specific antigen structure in regulating humoral responses? In line with their lack of detectable antibodies against HBsAg, patients with CHB are shown to have reduced numbers of functional HBsAg-specific responses by ELISpot compared to those with acute-resolving infection. However, application of fluorescently labeled antigen-bait systems was able to reveal for the first time that HBsAg-specific B cells in fact persist at equivalent levels in patients with chronic or acute-resolving infection and HBV-vaccinated controls but are functionally defective, failing to produce detectable anti-HBs upon stimulation in vitro. Comparatively, HBcAg-specific B cells are present at much higher frequencies than HBsAg-specific B cells, with their number associated with elevated liver inflammation and ongoing viral replication. In stark contrast to HBsAg-specific B cells, HBcAg-specific B cells maintain an ability to secrete anti-HBc antibodies upon IL-2, IL-21 and CD40 stimulation. These data therefore suggest that the absence of anti-HBs in patient sera is a result of defective HBsAg-specific B cells rather than a complete loss of this B cells with HBsAg-specificity.

These observations have stimulated detailed studies investigating the phenotype of B cells targeting HBsAg and HBcAg, providing insights into the differential regulation of B cell responses by antigen. Flow cytometric characterization revealed that HBsAg-specific B cells in patients with CHB were enriched for a CD27 CD21 FcRL5 T-bet atypical memory B cell phenotype. These atypical memory B cells (atMBCs)—also referred to as “tissue-like memory B cells” and with similarities to “age-associated B cells”—arise aberrantly in chronic infection, where they display impaired antibody-secreting cell differentiation, antiviral effector function, and survival compared with conventional CD27 memory B cells. Therefore, their presence within the HBsAg-specific B cell compartment is consistent with these cells contributing to defective anti-HBs responses in patients with CHB. Parallel analysis of HBsAg- and HBcAg-specific B cells by Le Bert et al., revealed that HBcAg-specific B cells were transcriptionally distinct from HBsAg-specific B cells, highlighting the ability of HBcAg and HBsAg to elicit distinct and dichotomous programs of differentiation and function. Unlike HBsAg-specific B cells, HBcAg-specific B cells were phenotypically dominated by IgG-switched CD27 CD21 classical memory B cells (cMBCs), which persist long-term independently of antigen and retain the capacity to proliferate and differentiate upon secondary exposure faster than naive B cells. Hence, the comparative dominance of atMBCs and cMBCs in HBsAg- and HBcAg-specific responses respectively may explain the difference in the formation of productive and long-lived humoral responses.

Antigen-experienced atMBCs have been described in many different infection settings and are thought to represent a distinct memory B cell population that diverges from cMBCs. Their presence in these contexts may give some clues as to factors that perturb memory B cell responses in chronic infections (summarized in Figure 1). Accumulating evidence suggests that atMBCs arise following repeated antigen challenge in an inflammatory setting inferring that these cells are perpetuated by persistent antigenic stimulation in support, the frequency of atMBCs observed in HIV infection falls in line with treatment-induced reductions in viral load and in those that spontaneously resolve infection. Thus, the accumulation of these cells in CHB appears to be, at least in part, driven by chronic exposure to HBV-viral proteins, as evidenced by the higher frequency of atMBCs in patients with ongoing infection compared with vaccinated or resolved controls. In addition to secreting full replicating virions, HBV-infected hepatocytes also release vast quantities of subviral particles—or “empty” viruses comprised of HBsAg in various sizes. These subviral particles flood the system, outnumbering infectious virus by 1000- to 100 000-fold, and may be responsible for subverting functional adaptive immune responses. It therefore follows that atMBCs are enriched within the HBsAg-specific fraction during acute and chronic infection and decline with resolution of disease. Although the frequency and phenotype of HBsAg-specific B cells did not associate with serum measurements of HBsAg load, levels of HBsAg in the circulation are not necessarily representative of HBsAg load within the liver and can fluctuate significantly throughout the course of infection. New therapeutic approaches (including therapeutic antibodies) to substantially lower HBsAg load in patients may now reveal a role for HBsAg load in maintaining memory B cell abnormalities. Nevertheless, these data raise the possibility that atMBCs accumulate over time, suggesting that pediatric patients infected perinatally or early in life may have lower levels of atMBCs and thus a greater potential to rescue humoral immunity; how infection shapes memory B cell responses and humoral immunity at different stages in life has yet to be explored in detail and may provide important insights into the optimal time to begin antiviral treatment.

In HIV infection and CHB, T-bet atMBCs express high levels of inhibitory receptors, including FcRL5 and PD-1, and are refractory to BCR stimulation in vitro. While these studies posit that atMBCs are a dysfunctional subset with impaired antiviral effector function, more recent work suggests that T-bet B cells represent a normal component of the human immune response that expand in certain pathological settings and can be induced following prophylactic vaccination and acute infection. T-bet-expressing B cells detected in the circulation shortly after vaccination have been proposed to represent a pre-plasmablast or pre-plasma cell pool due their upregulated expression of plasma cell transcription factor Blimp-1 and other plasma cell-related transcripts. Routinely influenza vaccination induces a population of antigen-specific T-bet memory B cells that correlate with the induction of effective humoral responses upon antigen re-challenge, suggesting that CD11c T-bet MBCs can resemble a GC-derived, effector-like population able to be recalled upon secondary antigen exposure. T-bet expression in B cells has been shown in mice to drive isotype switching toward antiviral IgG2a (equivalent to IgG1 in humans), with T-bet B cells shown to dominate gp140-specific responses and associate with a bias of specific serum immunoglobulin toward IgG1 in patients with HIV. These studies suggest that the function and contribution of T-bet memory B cells may differ according to context and may be restrained by inhibitory receptor expression induced following persistent antigen stimulation in settings of chronic
infection. In line with this, PD-1 blockade was shown to boost anti-HBs and antiviral cytokine responses by HBsAg-specific B cells in patients with CHB, in accordance with previous studies showing enhanced memory B cell proliferation and SIV-specific antibody production following in vivo PD-1 blockade in SIV-infected macaques.

B cell responses may also be affected where ongoing antigen production occurs alongside low-level antibody responses. In CHB, suboptimal antibody production is thought to coalesce with high circulating levels of HBsAg, resulting in the sequestration of available antibody in the form of immune complexes. Complexed antigen may not only reduce the availability of antibodies to target the virus, but have wide-ranging impacts on B cell function and humoral immunity through their action on Fc receptors. A recent study by Kardava et al. revealed that IgG3 can bind and suppress IgM-BCR signaling in tissue-like memory B cells from HIV-viremic patients, with assistance from FcγRIIB expression, complement and inflammatory components. Thus, the quantity of antigen may not only dictate memory B cell phenotype and function but sequester antibody and regulate humoral immunity through the formation of immune complexes.

Humoral immunity may also be regulated via properties intrinsic to the antigen in question. A key differential between HBcAg- and HBsAg-specific responses is the ability of HBcAg to promote B cell differentiation and isotype switching independently of CD4 T cell help. HBcAg is distinct from HBsAg in its capacity to self-assemble into highly immunogenic virus-like particles that can bind and activate naive B cells in a T cell-independent fashion. Due to its particulate, multivalent properties, HBcAg can crosslink membrane immunoglobulin receptors, facilitating efficient antigen presentation and co-stimulation by HBcAg-specific B cells to resting naive T
helper cells in vivo. These structural characteristics appear to allow HBcAg-specific B cells to bypass conventional T cell help and generate large extrafollicular antibody responses in the first instance. This capability is reflected in the kinetics of the anti-HBc antibody response throughout the course of infection, where early detection of anti-HBc IgM is progressively replaced by IgG isotype-switched antibody, evoking a switch from T cell-independent plasmablast-dominated responses to GC-derived immunity. Interestingly, anti-HBc IgM can re-appear where patients with CHB experience flares in disease and liver inflammation, possibly reflecting a burst in plasmablast responses triggered by an efflux of new HBcAg released following liver damage.

4 | EXTRAFOLICULAR DIFFERENTIATION VS THE GC RESPONSE

Although predominantly thought to represent a GC-derived memory B cell population, a growing school of thought suggests that T-bet expressing B cells (such as those seen in patients with CHB) may contribute to extrafollicular plasmablast responses under certain conditions. In SLE, extrafollicular responses are maintained by CD11c+ activated naïve B cells that differentiate into double-negative (DN2) B cells lacking IgD and CD27. These DN2 cells phenotypically resemble atMBCs in their high expression of T-bet and downregulation of CXCR5 and CD21 and are epigenetically poised toward antibody-secreting cell differentiation. As such, the expansion of CD11c+ T-bet+ B cells in CHB and other infections may be indicative of viral persistence interrupting GC formation and permitting the extrafollicular response to dominate.

Two recent studies have investigated a role for extrafollicular B cells in the immunopathology and apparent short-lived immunity observed following severe SARS-CoV-2 infection. Most COVID-19 patients seroconvert within 7-14 days of infection, with neutralizing antibodies that block the interaction between the “spike” glycoprotein of SARS-CoV-2 and its cellular receptor angiotensin-converting enzyme 2 (ACE-2) detected in the vast majority of recovered individuals. Strong neutralizing antibody titers and robust antigen-specific memory B cell and circulating T FH (cT FH) responses have previously been demonstrated in patients who experience a mild infection, with class-switched memory B cells targeting the receptor-binding domain (RBD) of the spike protein shown to persist for at least 3-6 months post-asymptom onset. Although titers of neutralizing antibodies are likely to wane following resolution of infection, persisting populations of memory B cells could provide durable humoral immunity capable of diversifying in the face of a mutating virus. However, studies demonstrating disruption of GC responses during acute COVID-19 have raised concerns that T cell-dependent, class-switched memory B cell differentiation may be impaired in patients experiencing severe COVID-19 disease. Histological analysis of patients hospitalized with acute SARS-CoV-2 infection revealed a loss of GCs in lymph nodes and spleens compared to control samples. These observations were associated with a decreased frequency of Bcl-6+ GC B cells and T FH cells, together with a bias toward T-bet+ T helper-1 cells (T FH), extrafollicular TNF-α production and increased frequencies of activated IgD-CD27 CXCR5+CD11c+ DN2 B cells, recently implicated in severe cases of COVID-19 disease. As such, although initial recruitment of DN2 B cells may play a role in providing early neutralizing responses associated with a good outcome of infection, the absence of Bcl-6+ T FH cells and loss of conventional GCs in the earliest stages of infection may preclude the generation of long-lived immunity. Thus, disruption of GC responses provides a mechanistic basis that could explain the non-durable humoral immunity and bias toward plasmablast responses observed in some COVID-19 patients.

An excessive plasmablast response may also play a role in driving immunopathology in the most severe cases of COVID-19, with plasmablast dominance in the early B cell response putatively linked to poor clinical outcome. Analysis of 125 hospitalized COVID-19 patients revealed an immune phenotype of patients with the most severe pathology, characterized by weak induction of cT FH responses and expansion of T-bet+ plasmablasts (in contrast to those with better clinical outcomes where B cell responses contained T-bet+ memory B cells). These data suggest that T cell-independent plasmablast responses may be responsible for the large antibody production observed in patients with severe disease. Similarly, anti-HBc IgM in germline configuration has been implicated in HBV-associated liver failure and exacerbations of disease in patients with CHB and may trigger complement-mediated lysis leading to liver necrosis. Therefore, while plasmablast responses can provide early control during infection, excessive plasmablast-derived antibody production following infection, alongside a delay in the emergence of the GC response, may play a key role in driving immunopathology.

The balance of the GC vs extrafollicular responses in the evolution of HBsAg-specific memory B cell responses in CHB has not been previously studied; however, HBsAg-specific IgG+ B cells from HBV-vaccine responders, as well as patients who spontaneously resolve chronic infection, show evidence of clonal expansion and somatic hypermutation, indicative of robust GC induction where protective immunity is established. Evidence from chronic infection suggests that HBsAg-specific B cells undergo minimal class-switching in contrast to HBcAg-specific B cells, although the level of somatic hypermutation within these populations has not been determined. An expansion of analogous HBsAg-specific T-bet+(CXCR5+ CD11c+) B cells in CHB may therefore represent preferential activation of extrafollicular responses toward HBsAg in CHB, triggered by a lack of viral control at the infection site and GC suppression, offering a potential explanation as to the lack of long-lived plasma cell formation and high affinity memory responses in chronic infection. However, studies in LCMV infection suggest that GC responses can operate effectively even when faced with high amounts of viral antigen, establishing a pool of high affinity antibody responses with neutralizing capacity that evolve throughout the course of chronic infection. Comparing acute and chronic infection in parallel, showed that the repertoire and function of antibody responses diverge during the early stages of infection, culminating in long-lasting
high affinity plasma cell responses in chronic infection. It may be, therefore, that CD11c+ T-bet+ B cells differ according to context, with those arising following acute infection representing extrafollicular B cells adept at producing early antibody responses, in contrast to exhausted or dysfunctional memory B cells that persist following chronic viral infection. Understanding the reasons for this loss of long-lived plasma cell and memory B cell formation in CHB will require architectural studies of lymphoid organs, coupled with detailed analyses of cell-cell interaction, yet may provide a mechanistic basis explaining the lack neutralizing anti-HBs formation in CHB.

5 | CD4 T CELL DETERMINATION OF B CELL FATE

Since GC formation and function are critically dependent on Th17 cell function, defective humoral immunity is closely associated with impaired CD4 T cell differentiation. The induction of broad and functional CD4 T cell responses is essential to reducing viral loads and establishing functional antibody-mediated production. Viral persistence can be established where CD4 T cell frequencies are diminished, with CD4 T cell dysfunction in HIV-1 infection precluding full recovery of the B cell response upon antiviral treatment. Early studies investigating defective anti-HBs production in CHB suggested that persistent infection subverts protective CD4+ T helper responses, in turn suppressing anti-HBs production. Co-culture assays using allogeneic B cells from HBV-vaccinated responders and T cells from patients with CHB failed to produce detectable anti-HBs responses, pointing to the existence of B cell-specific defects in combination with impaired CD4 T cell help.

Similar to CD8+ T cells, HBV-specific CD4+ T helper cells show evidence of lymphocyte exhaustion, with decreased expression of the co-stimulatory molecule OX40 on circulating CD4+ T cells associated with viral persistence. Defective Th1 responses towards HBsAg may be further restrained by expanded numbers of T follicular regulatory cells in chronic infection, as suggested by mouse models. Anti-HBc responses seem to be protected due to their ability to bypass CD4 T cell help, establishing early plasmablast responses and antibody production in germline configuration.

While Th1 are therefore essential for inducing T cell-dependent antibody production, the communication between CD4+ T cells and B cells following initial antigen stimulation is also critical to determining B cell fate. Emerging data suggest that T-bet expression in B cells is dependent on CD4+ T cell help, with adoptive transfer studies indicating that T-bet+ B cells fail to form in the absence of MHC-II or CD40-mediated interactions. Combined with observations that IFN-γ or IL-21 stimulation drives T-bet in B cells, these data suggest that T-bet+ B cell generation is supported by Th1-biased T cell help.

Such Th1-like conditions have been shown to prevail in chronic infection and therefore may be responsible for diverting T-bet+ B cell differentiation in these settings (Figure 1). In mouse models of malaria infection, Th17 cells induced following infection displayed low levels of the archetypal Th1 markers, PD-1 and CXCR5, instead co-expressing Th17-associated markers, T-bet and CXCR3. This phenotype was associated with an absence of GC, which was restored upon blockade of inflammatory cytokines, TNF-α and IFN-γ or deletion of T-bet, suggesting that Th1-skewed Th17 responses may be responsible for diverting GC responses toward extrafollicular differentiation. Similarly, Th17-associated conditions have been demonstrated to regulate expression of T-bet and lymph node positioning receptors in B cells, resulting in the exclusion of T-bet+ B cells from the GC and their accumulation in non-GC areas of the lymph node in both patients with HIV infection and healthy controls. Here, HIV-specific T-bet+ B cells were transcriptionally distinct from those isolated HIV-naive controls, displaying a lower frequency of somatic hypermutation relative to GC B cells and T-bet- memory precursors and reduced capacity to neutralize virus in vitro.

Thus, CD4 T cells are central to determining the positioning and resultant downstream differentiation of B cell responses and are in turn differentially regulated in acute or chronic infection. This was elegantly demonstrated by De Giovanni et al., who used an adoptive transfer model to investigate differences in Th1 responses between acute (vesicular stomatitis virus; VSV) and chronic (LCMV) infection. Early induction of Type I IFN during VSV infection promoted IL-6 production by dendritic cells, driving Th1 cell differentiation and proliferation. In contrast, late exposure occurring during infection with LCMV failed to induce IL-6, instead promoting Th1 cell differentiation. In vivo imaging of the GC response in this setting revealed that Th1-biased CD4 T cells in LCMV infection were confined to the areas outside of the B cell follicle, providing insight into the mechanism by which CD4 T cell help may direct extrafollicular localization and differentiation of B cells.

6 | MEMORY IN PERIPHERAL TISSUES

Differences in chemokine receptor expression by memory B cell subsets may facilitate their differential trafficking ability and accumulation outside of the lymph node and in non-lymphoid tissues. T-bet+ atMBCs and DN2 B cells have low surface expression of CXCR5 critical to lymph node homing and entry to the B cell follicle, instead expressing high levels of the inflammatory tissue-homing marker CXCR3 and the integrin CD11c. As a result, T-bet+ B cells are largely absent from lymph nodes but identifiable in the blood, bone marrow, and spleen where they localize at the T:B cell border and can become resident, losing the ability to recirculate. FcRL4+ B cells, with many characteristics analogous of atMBCs, were described in the tonsils at much higher frequencies than that detected in the blood and bone marrow, suggesting that they may represent a specialized tissue-based subpopulation of memory B cells. In line with this, we previously identified an expansion of CD21+CD27+ T-bet+CD11c+ memory B cells within the global and HBsAg-specific B cell compartment in the liver relative to the blood. The frequency of intrahepatic atMBCs was further increased in HBV-infected livers compared with healthy controls, implicating a combined effect of the liver milieu and virus in driving this expansion.
The demonstration of antigen-specific T-bet+ B cells in non-lymphoid tissues may have important implications for local tissue-based immunity. Memory B cells localized with tissues are likely poised to make antibody following a secondary encounter with antigen, for example influenza-specific B cells residing in the lung rapidly differentiate in situ to provide rapid responses upon secondary infection in influenza-infected mice. In HBV infection, local production of anti-HBs antibodies may accelerate pathogen clearance and assist in blocking de novo infection of hepatocytes or promoting ADCC-mediated elimination of infected cells.

It is also plausible that tissue-localized B cells may be capable of participating in ectopic GC reactions. It has long been described that tertiary lymphoid structures resembling GCs can arise in non-lymphoid tissues and assist in the activation, proliferation, and differentiation of B cell responses. The formation of ectopic GCs is dependent on the preparation and remodeling of peripheral tissues into one reminiscent of secondary lymphoid organs (SLO) capable of supporting GC responses. Viral infection has been clearly shown to support lung remodeling following influenza infection: Type I IFN produced in response to infection rapidly induces CXCL13, in turn driving B cell recruitment and lung remodeling to facilitate the formation of ectopic GCs. These responses can have profound benefits for local immunity; for example, the development of ectopic GCs in the lung following Influenza-A infection is sufficient to prime antigen-specific T and B cell responses independently of SLO-derived responses to protect against secondary infection and can generate memory B cells and plasma cells with greater cross-reactive potential to enhance protection against highly mutating viruses.

Intrahepatic lymphoid follicles (ILFs) with features of ectopic GCs (including Bcl-6 and Ki67) are well-documented in Hepatitis C virus (HCV) infection and are postulated to facilitate expansion of both HCV-specific and autoreactive clones. In comparison, B and T cell aggregates in patients with CHB have been shown to lack a well-formed GC, suggesting that an absence of mature tissue-based responses may contribute to overall impaired humoral immunity in CHB. A recent paper testing the immunotherapeutic effects of TLR-7 agonists in HBV-infected chimpanzees demonstrated a transient induction of these aggregates coinciding with prolonged suppression of serum viral DNA and antigens. Although preliminary investigation suggested that these structures did not contain GC reactions, the association between the formation of these structures and antiviral response to treatment suggested that they may play a role in promoting an effective response against HBV. Further in-depth analysis is required to investigate whether memory B cells can become activated and differentiate within the liver or traffic to the liver post-activation, and how this affects the development and maintenance of local humoral responses.

Whether intrahepatic B cells represent a transient population circulating through the highly vascularized liver, or a pool of resident B cells capable of persisting in the liver long-term is not currently known. A growing body of evidence suggests that viral infection may seed populations of tissue-resident B cells with the capacity to remain within peripheral tissues and provide lasting protection against secondary infection. Influenza-specific B cells have been demonstrated to accumulate in the lung where they can persist for up to five months following resolution of infection and secrete high levels of neutralizing antibodies in the local microenvironment. As with tissue-resident T cells, emerging data suggest that B cells responding to infection at a peripheral site are imprinted by local antigen encounter within the lung, allowing them to acquire homing capabilities that facilitate their in situ differentiation and retention within the tissue shortly after infection. Mice with enriched influenza-specific tissue-resident B cell populations in the lung responded more rapidly than mice with memory B cells at systemic sites due to the rapid differentiation of Bm into antibody-producing plasma cells directly at the site of infection. The selection of B cells that seed these tissue-resident compartments might therefore determine the specificity and affinity of local responses to viral antigens during secondary responses and may explain the broad reactivity of ectopic GC responses observed.

7 | OUTLOOK

To date, the study of humoral immunity to viral infections has predominantly focused on antibodies rather than the cells responsible for producing these effector molecules. Following the resolution of an acute infection like COVID-19, antibodies may wane in some individuals over time, underscoring the importance of determining whether memory B cells of the correct specificity persist to allow a rapid response upon re-infection. In a chronic infection like CHB where anti-HBs antibodies are undetectable, identification of persistent HBsAg-specific memory B cells has raised the possibility that endogenous humoral immunity could be revived by identifying the defects limiting their function. Thus, recent studies using fluorescent baits to characterize antigen-specific B cell responses from patients with acute infections like COVID-19 and chronic infections like HBV have started to expand our understanding of the complexity of memory B cell responses. Flow cytometric analysis has allowed their ex vivo quantification and phenotypic characterization, revealing memory subsets with different isotype expression, homing patterns, and signatures of Tfh interactions and GC reactions, as well as transcriptional factors determining antiviral potential such as T-bet.

However, the level of characterization of memory B cells still lags far behind that of T cells in viral infections and much remains to be learnt. In addition to targeted phenotypic analysis, unbiased profiling combining RNA-sequencing with B cell receptor analysis will allow more comprehensive characterization of memory B cell responses. Analysis of B cells specific for different viral antigens, carried out in tandem with antigen-specific Tfh responses and focused analysis of pathways such as CD40/CD40-L, will help to determine their potential for productive interaction. Longitudinal analyses during dynamic phases of infection will clarify their temporal kinetics, as exemplified by the recent demonstration that spike-specific memory B cells continue to increase in frequency.
in the 6 months following COVID-19 infection.\textsuperscript{68} Where possible, parallel analyses of memory B cell and plasma cell responses in lymph nodes, gut and bone marrow will give a better understanding of how well circulating frequencies and phenotypes reflect humoral antiviral immunity sequestered in these compartments. Similarly, our demonstration that HBsAg-specific B cells can be identified in human liver\textsuperscript{22} reinforces the need for more in-depth studies of memory B cells compartmentalized in the liver and in other settings of virally infected non-lymphoid organs such as the lungs in COVID-19.

ACKNOWLEDGEMENTS

ARB and MKM are funded by a WT Investigator award (101849/Z/13/A) and a NIHR EME grant.

CONFLICT OF INTEREST

MKM has received collaborative research funding from Gilead Sciences, F. Hoffmann-La Roche and Immunocore and has served as a consultant or on advisory boards for Gilead Sciences, F. Hoffmann-La Roche, Immunocore and GSK. MKM and ARB have filed IP on a method to enhance HBV-specific immune responses.

ORCID

Alice R. Burton  \textsuperscript{https://orcid.org/0000-0003-1049-1176}
Mala K. Maini  \textsuperscript{https://orcid.org/0000-0001-6384-1462}

REFERENCES

1. Lam JH, Smith FL, Baumgarth N. B cell activation and response regulation during viral infections. \textit{Viral Immunol}. 2020;33:294-306.
2. Allman D, Wilmore JR, Gaudette BT. The continuing story of T-cell independent antibodies. \textit{Immunol Rev}. 2019;288:128-135.
3. Di Niro R, Lee S-J, Vander Heiden J, et al. Salmonella infection drives promiscuous B cell activation followed by extrafollicular affinity maturation. \textit{Immunity}. 2015;43:120-131.
4. Bohannon C, Powers R, Satyabhama L, et al. Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection. \textit{Nat Commun}. 2016;7:11826.
5. Khoo LHB, Thiam CH, Soh SY, Angeli V. Splenic extrafollicular re- actions and BM plasma cells sustain IgM response associated with hypercholesterolemia. \textit{Eur J Immunol}. 2015;45:1300-1312.
6. Oliviero B, Cerino A, Varchetta S, et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. \textit{J Hepatol}. 2011;55:53-60.
7. Cerino A, Bremer CM, Glebe D, Mondelli MU. A human monoclonal antibody against hepatitis B surface antigen with potent neutralizing activity. \textit{PLoS One}. 2015;10:e0125704.
8. Glebe D, Aliakbari M, Krasp P, Knoop EV, Valerius KP, Gerlich WH. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. \textit{J Virol}. 2003;77:9511-9521.
9. Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. \textit{J Hepatol}. 2016;64:S71-S83.
10. Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. \textit{Nat Rev Gastroenterol Hepatol}. 2019;16:662-675.
11. Huang K-HG, Bonsall D, Katzourakis A, et al. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. \textit{Nat Commun}. 2010;1:102.
12. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies and future directions. \textit{Gastroenterology}. 2017;152:1297-1309.
13. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. \textit{Semin Liver Dis}. 2013;33:167-177.
14. Hammarlund E, Amanna IJ, et al. Plasma cell survival in the absence of B cell memory. \textit{Nat Commun}. 2017;8:1781.
15. Hehle V, Beretta M, Bourgine M, et al. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. \textit{J Exp Med}. 2020;217:e20200840.
16. Wang Q, Michaelides E, Ku Y, et al. A combination of human broadly neutralizing antibodies against hepatitis B virus HBsAg with distinct epitopes suppresses escape mutations. \textit{Cell Host Microbe}. 2020;28:335-349.e6.
17. Barnaba V, Valesini G, Bevero M, et al. Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients. \textit{Clin Exp Immunol}. 1985;60:259-266.
18. Böcher WO, Herzog-Hauf Schlaak J, Meyer-zum-Büschenfeld KH, Lühr HF. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. \textit{Hepatology}. 1999;29:238-244.
19. Dusheiko GM, Hoofnagle JH, Cooksley WG, James SP, Jones EA. Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers. \textit{J Clin Invest}. 1983;71:1104-1113.
20. Wang Q, Sachse P, Semmo M, et al. T- and B-cell responses and previous exposure to hepatitis B virus in ‘anti-HBc alone’ patients. \textit{J Virol Hepat}. 2015;22:1068-1078.
21. Xu X, Shang Q, Chen X, et al. Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. \textit{Cell Mol Immunol}. 2015;12:309-316.
22. Burton AR, Pallett LJ, McCoy LE, et al. Circulating and intrahepatic anti viral B cells are defective in hepatitis B. \textit{J Clin Invest}. 2018;128:4588-4603.
23. Salimzadeh L, Le Bert N, Dutertre C-A, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. \textit{J Clin Invest}. 2018;128:4573-4587.
24. Le Bert N, Salimzadeh L, Gill US, et al. Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B. \textit{J Hepatol}. 2020;72:34-44.
25. Vanwolleghem T, Groothuisink ZMA, Kreeft E, et al. Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV. \textit{J Hepatol}. 2020;73:52-61.
26. Poonia B, Ayithan N, Nandi M, Masur H, Kottilly S. HBV induces inhibitory FcRl receptor on B cells and dysregulates B cell-T follicular helper cell axis. \textit{Sci Rep}. 2018;8:15296.
27. Charles ED, Green RM, Marukian S, et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. \textit{Blood}. 2008;111:1344-1356.
28. Isnardi I, Ng Y-S, Menard L, et al. Complement receptor 2/CD21-human naive B cells contain mostly autoreactive unresponsive clones. \textit{Blood}. 2010;115:5026-5036.
29. Portugal S, Tipton CM, Sohn H, et al. Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function. \textit{eLife Sciences}. 2015;4:e07218.
30. Maruyama M, Lam KP, Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. \textit{Nature}. 2000;407:636-642.
31. Crotty S, Felgner P, Davies H, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. \textit{J Immunol}. 2003;171:4969-4973.
32. Good KL, Averv DT, Tangye SG. Resting human memory B cells are intrinsically programmed for enhanced survival and
responsiveness to diverse stimuli compared to naive B cells. J Immunol. 2009;182:890-901.

33. Tangye SG, Avery DT, Deenicik EK, Hodgkin PD. Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J Immunol. 2003;170:686-694.

34. Knox JJ, Myles A, Cancro MP. T-bet+ memory B cells: generation, function, and fate. Immuno Rev. 2019;288:149-160.

35. Portugal S, Obeng-Adjei N, Moir S, Crompton PD, Pierce SK. Atypical memory B cells in human chronic infectious diseases: an interim report. Cell Immunol. 2017;321:18-25. https://doi.org/10.1016/j.cellimm.2017.07.003

36. Fogli M, Torti C, Malacarne F, et al. Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naive for HAART is related to reduced immune surveillance. Clin Dev Immunol. 2012;2012:829584.

37. Amu S, Lavy-Shahaf G, Cagigi A, et al. Frequency and phenotype of B cell subpopulations in young and aged HIV-1 infected patients receiving ART. Retrovirology. 2014;11:76.

38. Ferreira CB, Merino-Mansilla A, Llano A, et al. Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations. J Virol. 2013;87:12227-12236.

39. Sciaranghella G, Tong N, Mahan AE, Suscovich TJ, Alter G. Long CD21 expression defines a population of recent germinal center graduates primed for plasma cell responses. J Immunol. 2017;2017:2:e92943. https://doi.org/10.1172/JCI142966

40. Muema DM, Macharia GN, Hassan AS, et al. Control of viremia in asymptomatic HIV-1-infected individuals. Nat Immunol. 2018;19:1001-1012. https://doi.org/10.1038/s41590-018-0180-5

41. Racine R, Chatterjee M, Winslow GM. CD11c expression identifies as a mechanism for enhanced secondary immune responses. Cell Immunol. 2003;170:686-694.

42. Juno JA, Tan H-X, Lee WS, et al. Humoral and circulating follicular helper T cell responses correlate with neutralizing antibodies and morbidity in COVID-19 patients. J Immunol. 2020;19:1071-1082.

43. Kim CC, Baccarella AM, Bayat A, Pepper M, Fontana MF. FcRl5+ memory B cells exhibit robust recall responses. Cell Rep. 2019;27:1446-1460.e4.

44. Barnett BE, Staupe RP, Odorizzi PM, et al. Cutting edge: B cell-intrinsic T-bet expression is required to control chronic viral infection. J Immunol. 2016;197:1017-1022.

45. Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458:206-210.

46. Gerlich WH. The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg. Clin Infect Dis. 2007;44:1170-1172.

47. Nimmerjahn F, Ravetch JV. Fc\[gamma\] receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34-47.

48. Kardava L, Sohn H, Youn C, et al. IgG3 regulates tissue-like memory B cells in HIV-infected individuals. Nat Immunol. 2018;19:1001-1012. https://doi.org/10.1038/s41590-018-0180-5

49. Kim CC, Baccarella AM, Bayat A, Pepper M, Fontana MF. FcRl5+ memory B cells exhibit robust recall responses. Cell Rep. 2019;27:1446-1460.e4.

50. Barnett BE, Staupe RP, Odorizzi PM, et al. Cutting edge: B cell-intrinsic T-bet expression is required to control chronic viral infection. J Immunol. 2016;197:1017-1022.

51. Nimmerjahn F, Ravetch JV. Fc\[gamma\] receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34-47.
